The Forgotten Frontline: Are Incomplete UC Deployments Causing Avoidable Risk?
Ineo Expands MoveTrack™ Global Compensation Capabilities With Integrated Global Gross-Up Across 100+ Countries
Society Pass Incorporated (Nasdaq: SOPA) and NusaTrip Incorporated (Nasdaq: NUTR) Strengthened its Presence in the Tourism Market with Collaboration with Qi You Ji Network Technology Co. Limited
University of Louisiana Monroe Enhances Campus Safety with SkySafe
Zuken Vitech Announces Sidekick v1.1, Advancing Collaboration and Communication in Model-Based Systems Engineering
WARREN, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical…
SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company…
REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a…
New preclinical data expand understanding of α4β7-expressing immune cells and MORF-057 dose response Data support…
ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical…
ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease Immix Biopharma, Inc….
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX),…
CAMARILLO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech…
CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical…
– ARCALYST® (rilonacept) net revenue of $18.7 million in Q4 2021 and $38.5 million in 2021…
CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies…
Dr. Galamidi joins Enlivex after 10 years at Gamida Cell Ltd., where she most recently…
Study evaluating the efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL,…
Creates late-stage, diversified pipeline that uses a multi-targeted approach to reset dysregulated biology to address…
MELBOURNE, Australia, Feb. 22, 2022 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE,…
– Collaboration includes rights to develop and commercialize ARCALYST® and mavrilimumab in the Asia Pacific…
FORT COLLINS, Colo., Feb. 22, 2022 (GLOBE NEWSWIRE) — Statera Biopharma, Inc. (NASDAQ: STAB) (the…
PHILADELPHIA, Feb. 22, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:…
MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
OTO-313 Phase 2 trial is fully enrolled ahead of schedule Top-line results for all timepoints…